INmune Bio Completes Phase I/II Trial for INKmune™

The latest update is out from Inmune Bio ( (INMB) ).

On August 4, 2025, INmune Bio announced the successful completion of its Phase I/II trial for INKmune™ in treating metastatic castration-resistant prostate cancer, having met its primary and secondary endpoints. The company also released its second-quarter financial results, highlighting a net loss of $24.5 million and a strategic management reshuffle with David Moss appointed as the new President & CEO. The announcement indicates a strategic focus on advancing its therapeutic platforms and strengthening its market position through partnerships and patent developments, despite financial challenges.

The most recent analyst rating on (INMB) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.

Spark’s Take on INMB Stock

According to Spark, TipRanks’ AI Analyst, INMB is a Neutral.

Inmune Bio’s overall stock score is hindered by significant financial challenges, including declining revenue and ongoing losses. While technical analysis shows mixed signals, valuation metrics suggest overvaluation. Positive corporate events and earnings call highlights provide some optimism, but financial instability and operational challenges remain key risks.

To see Spark’s full report on INMB stock, click here.

More about Inmune Bio

INmune Bio Inc. is a clinical-stage immunology company focused on developing treatments that leverage the patient’s innate immune system to combat diseases. The company is involved in various therapeutic platforms, including DN-TNF, CORDStrom, and INKmune™, targeting conditions like Alzheimer’s, traumatic brain injury, and metastatic castration-resistant prostate cancer.

Average Trading Volume: 3,336,352

Technical Sentiment Signal: Sell

Current Market Cap: $71.51M

See more data about INMB stock on TipRanks’ Stock Analysis page.